Growth Opportunities in mRNA Therapeutics, Genomics Platforms, Microbiome Testing, Would Healing Solutions, and AI-Based Diagnostics - ResearchAndMarkets.com

·2 min read

DUBLIN, January 28, 2022--(BUSINESS WIRE)--The "Growth Opportunities in mRNA Therapeutics, Genomics Platforms, Microbiome Testing, Would Healing Solutions, and AI-Based Diagnostics" report has been added to ResearchAndMarkets.com's offering.

The increase in clinical utility of liquid biopsies and other diagnostic assays, which is driven by AI has been discussed. The TOE issue also highlights developments in enabling technologies for microbiome analysis, and personalized health solutions based on microbiome testing. A few emerging technologies around DNA synthesis, next generation mRNA therapeutics and diagnostics have been highlighted. Few innovations highlight developments in wound healing solutions, which include smart dressings and plant-based solutions.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Innovations in Life Sciences, Health & Wellness

  • Self-Amplifying, Programmable, Long-Acting mRNA Therapeutics

  • Self-Amplifying mRNA to Revolutionize mRNA Therapeutics

  • Strand Therapeutics - Investor Dashboard

  • Dgl-TechT, Chemirna Tech, and Spin-Tube for Nucleic Acid Diagnostics

  • Destina Geonomics' Technologies to Detect Different Types of Nucleic Acids With High Sensitivity and Specificity

  • Destina Genomics - Investor Dashboard

  • Express Dna Machine for DNA Oligo Designing

  • Kilobaser to Leverage Conventional Dna Synthesis With Proprietary Microfluidics Technology for Dna Oligos

  • Kilobaser - Investor Dashboard

  • Integrated Microbiome Analysis Solution

  • Cost-Effective Sequencing Approach

  • Microbiome Insights - Investor Lens

  • Microbiome-Based Personalized Health Solution

  • Technology Diagnosing Health Risks

  • Navipoint Health - Investor Lens

  • Synbio Driven Engineered Microbial Therapeutics

  • Technology to Reduce Phenylalanine

  • Synlogic - Investor Lens

  • Transparent Hydrogel Dressing With Colorimetric Sensors

  • 3D Printed Sensors for Wound Healing Detection

  • 4M Biotech - Investor Dashboard

  • Allantoin-Based Skin Protectant

  • Non-Cytotoxic Plant Extract for Faster Wound Healing

  • Lavior - Investor Dashboard

  • Microstaple Technology for Wound Closure

  • Microstaple Technology Eliminating the Need for Anasthesia

  • Kitotech Medical Inc. - Investor Dashboard

  • Ai Augmented Precision Molecular Diagnostics

  • Glycoproteomics-Based Diagnostics for Ovarian Cancer

  • Liquid Biopsy With Dual Approach for Cancer Diagnostics

  • Immunoassay for Differentiation of Bacterial and Viral Infections

  • Gene Therapy for Fabry Disease

Companies Mentioned

  • 4M Biotech

  • Destina Genomics

  • DGK-TechT

  • Kilobaser

  • Kitotech Medical Inc.

  • Lavior

  • Microbiome Insights

  • Navipoint Health

  • Strand Therapeutics

  • Synlogic

For more information about this report visit https://www.researchandmarkets.com/r/hzvh03

View source version on businesswire.com: https://www.businesswire.com/news/home/20220128005283/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900